Bristol-Myers says panel finds Opdivo lung cancer study meets endpoint

(Reuters) - Bristol-Myers Squibb Co said the independent data monitoring committee concluded that a late stage study evaluating Opdivo versus docetaxel in previously treated patients with advanced, squamous cell non-small cell lung cancer met its endpoint.

via Reuters: Health News Read More Here..

For a Free Step By Step Guide for Dating Dos and Don'ts check http://end2endwebs.com

Lake forest health and fitness http://ift.tt/1DOdmSC